Skip to main content
NCBI home page
Molecular Medicine logoLink to Molecular Medicine
. 1997 May;3(5):327–338.

Interleukin-4 receptor expression on AIDS-associated Kaposi's sarcoma cells and their targeting by a chimeric protein comprised of circularly permuted interleukin-4 and Pseudomonas exotoxin.

S R Husain 1, P Gill 1, R J Kreitman 1, I Pastan 1, R K Puri 1
PMCID: PMC2230073  PMID: 9205948

Abstract

BACKGROUND: AIDS-associated Kaposi's sarcoma (AIDS-KS) represents one of the most common malignancies associated with human immunodeficiency virus infection. To target effective therapeutic agents to AIDS-KS, we have identified a new target in the form of interleukin-4 receptors (IL-4R). MATERIALS AND METHODS: The expression of IL-4R on AIDS-KS cells and their subunit structure was determined by radioligand receptor binding, cross-linking and Northern and RT-PCR analyses. The in vitro effect of IL-4 and recombinant fusion protein made up of circularly permuted IL-4 and a mutated form of Pseudomonas exotoxin, IL-4(38-37)-PE38KDEL, was examined by clonogenic and protein synthesis inhibition assays. RESULTS: Five AIDS-KS cell lines expressed high-affinity IL-4R with a Kd of 23.5-219 pM. IL-4 appeared to cross-link to one major protein corresponding to 140 kDa and a broad band corresponding to 60-70 kDa. Both cross-linked proteins were immunoprecipitated with an antibody to human IL-4R beta chain. AIDS-KS cells exhibited IL-4R beta-specific mRNA. IL-4 caused a modest inhibition (31-34%) of colony formation in two AIDS-KS cell lines tested. IL-4(38-37)-PE38KDEL was found to be highly effective in inhibiting the protein synthesis in all five AIDS-KS examined. The IC50 ranged from 32 to 1225 pM. The cytotoxic action of IL-4 toxin was blocked by an excess of IL-4, exhibiting the specificity of IL-4(38-37)-PE38KDEL. The cytotoxicity of IL-4 toxin observed by a clonogenic assay corroborated well with the IC50 obtained by protein synthesis inhibition assay. Normal human endothelial cells expressed a negligible number of IL-4R (< 50 sites/cell) and were less sensitive or not sensitive to IL-4(38-37)-PE38KDEL. CONCLUSION: The presence of a new plasma membrane protein in the form of IL-4R on AIDS-KS cells may be targeted by IL-4(38-37)-PE38KDEL for its potential implication in the treatment of AIDS-KS.

Full text

PDF
327

Images in this article

331FIG. 3
on p.331
332FIG. 4
on p.332
335FIG. 6
on p.335

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Clerici M., Hakim F. T., Venzon D. J., Blatt S., Hendrix C. W., Wynn T. A., Shearer G. M. Changes in interleukin-2 and interleukin-4 production in asymptomatic, human immunodeficiency virus-seropositive individuals. J Clin Invest. 1993 Mar;91(3):759–765. doi: 10.1172/JCI116294. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Corbeil J., Evans L. A., Vasak E., Cooper D. A., Penny R. Culture and properties of cells derived from Kaposi sarcoma. J Immunol. 1991 May 1;146(9):2972–2976. [PubMed] [Google Scholar]
  3. Debinski W., Puri R. K., Kreitman R. J., Pastan I. A wide range of human cancers express interleukin 4 (IL4) receptors that can be targeted with chimeric toxin composed of IL4 and Pseudomonas exotoxin. J Biol Chem. 1993 Jul 5;268(19):14065–14070. [PubMed] [Google Scholar]
  4. Debinski W., Puri R. K., Pastan I. Interleukin-4 receptors expressed on tumor cells may serve as a target for anticancer therapy using chimeric Pseudomonas exotoxin. Int J Cancer. 1994 Sep 1;58(5):744–748. doi: 10.1002/ijc.2910580520. [DOI] [PubMed] [Google Scholar]
  5. Ensoli B., Barillari G., Gallo R. C. Pathogenesis of AIDS-associated Kaposi's sarcoma. Hematol Oncol Clin North Am. 1991 Apr;5(2):281–295. [PubMed] [Google Scholar]
  6. Ensoli B., Nakamura S., Salahuddin S. Z., Biberfeld P., Larsson L., Beaver B., Wong-Staal F., Gallo R. C. AIDS-Kaposi's sarcoma-derived cells express cytokines with autocrine and paracrine growth effects. Science. 1989 Jan 13;243(4888):223–226. doi: 10.1126/science.2643161. [DOI] [PubMed] [Google Scholar]
  7. Foxwell B. M., Woerly G., Ryffel B. Identification of interleukin 4 receptor-associated proteins and expression of both high- and low-affinity binding on human lymphoid cells. Eur J Immunol. 1989 Sep;19(9):1637–1641. doi: 10.1002/eji.1830190918. [DOI] [PubMed] [Google Scholar]
  8. Freedman V. H., Shin S. I. Cellular tumorigenicity in nude mice: correlation with cell growth in semi-solid medium. Cell. 1974 Dec;3(4):355–359. doi: 10.1016/0092-8674(74)90050-6. [DOI] [PubMed] [Google Scholar]
  9. Friedman-Kien A. E. Disseminated Kaposi's sarcoma syndrome in young homosexual men. J Am Acad Dermatol. 1981 Oct;5(4):468–471. doi: 10.1016/s0190-9622(81)80010-2. [DOI] [PubMed] [Google Scholar]
  10. Galizzi J. P., Castle B., Djossou O., Harada N., Cabrillat H., Yahia S. A., Barrett R., Howard M., Banchereau J. Purification of a 130-kDa T cell glycoprotein that binds human interleukin 4 with high affinity. J Biol Chem. 1990 Jan 5;265(1):439–444. [PubMed] [Google Scholar]
  11. Galizzi J. P., Zuber C. E., Cabrillat H., Djossou O., Banchereau J. Internalization of human interleukin 4 and transient down-regulation of its receptor in the CD23-inducible Jijoye cells. J Biol Chem. 1989 Apr 25;264(12):6984–6989. [PubMed] [Google Scholar]
  12. Ganem D. AIDS. Viruses, cytokines and Kaposi's sarcoma. Curr Biol. 1995 May 1;5(5):469–471. doi: 10.1016/s0960-9822(95)00093-5. [DOI] [PubMed] [Google Scholar]
  13. Gill P. S. Pathogenesis of HIV-related malignancies. Curr Opin Oncol. 1991 Oct;3(5):867–871. doi: 10.1097/00001622-199110000-00010. [DOI] [PubMed] [Google Scholar]
  14. Harada N., Yang G., Miyajima A., Howard M. Identification of an essential region for growth signal transduction in the cytoplasmic domain of the human interleukin-4 receptor. J Biol Chem. 1992 Nov 15;267(32):22752–22758. [PubMed] [Google Scholar]
  15. Hermans P., Gori A., Lemone M., Franchioly P., Clumeck N. Possible role of granulocyte-macrophage colony stimulating factor (GM-CSF) on the rapid progression of AIDS-related Kaposi's sarcoma lesions in vivo. Br J Haematol. 1994 Jun;87(2):413–414. doi: 10.1111/j.1365-2141.1994.tb04934.x. [DOI] [PubMed] [Google Scholar]
  16. Herrmann F., Andreeff M., Gruss H. J., Brach M. A., Lübbert M., Mertelsmann R. Interleukin-4 inhibits growth of multiple myelomas by suppressing interleukin-6 expression. Blood. 1991 Oct 15;78(8):2070–2074. [PubMed] [Google Scholar]
  17. Husain S. R., Leland P., Aggarwal B. B., Puri R. K. Transcriptional up-regulation of interleukin 4 receptors by human immunodeficiency virus type 1 tat gene. AIDS Res Hum Retroviruses. 1996 Sep 20;12(14):1349–1359. doi: 10.1089/aid.1996.12.1349. [DOI] [PubMed] [Google Scholar]
  18. Keegan A. D., Beckmann M. P., Park L. S., Paul W. E. The IL-4 receptor: biochemical characterization of IL-4-binding molecules in a T cell line expressing large numbers of receptors. J Immunol. 1991 Apr 1;146(7):2272–2279. [PubMed] [Google Scholar]
  19. Keegan A. D., Nelms K., Wang L. M., Pierce J. H., Paul W. E. Interleukin 4 receptor: signaling mechanisms. Immunol Today. 1994 Sep;15(9):423–432. doi: 10.1016/0167-5699(94)90272-0. [DOI] [PubMed] [Google Scholar]
  20. Kreitman R. J., Puri R. K., Pastan I. A circularly permuted recombinant interleukin 4 toxin with increased activity. Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):6889–6893. doi: 10.1073/pnas.91.15.6889. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Kreitman R. J., Puri R. K., Pastan I. Increased antitumor activity of a circularly permuted interleukin 4-toxin in mice with interleukin 4 receptor-bearing human carcinoma. Cancer Res. 1995 Aug 1;55(15):3357–3363. [PubMed] [Google Scholar]
  22. Masood R., Husain S. R., Rahman A., Gill P. Potentiation of cytotoxicity of Kaposi's sarcoma related to immunodeficiency syndrome (AIDS) by liposome-encapsulated doxorubicin. AIDS Res Hum Retroviruses. 1993 Aug;9(8):741–746. doi: 10.1089/aid.1993.9.741. [DOI] [PubMed] [Google Scholar]
  23. Miles S. A. Pathogenesis of HIV-related Kaposi's sarcoma. Curr Opin Oncol. 1994 Sep;6(5):497–502. doi: 10.1097/00001622-199409000-00009. [DOI] [PubMed] [Google Scholar]
  24. Mosley B., Beckmann M. P., March C. J., Idzerda R. L., Gimpel S. D., VandenBos T., Friend D., Alpert A., Anderson D., Jackson J. The murine interleukin-4 receptor: molecular cloning and characterization of secreted and membrane bound forms. Cell. 1989 Oct 20;59(2):335–348. doi: 10.1016/0092-8674(89)90295-x. [DOI] [PubMed] [Google Scholar]
  25. Munson P. J., Rodbard D. Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem. 1980 Sep 1;107(1):220–239. doi: 10.1016/0003-2697(80)90515-1. [DOI] [PubMed] [Google Scholar]
  26. Murakami-Mori K., Taga T., Kishimoto T., Nakamura S. AIDS-associated Kaposi's sarcoma (KS) cells express oncostatin M (OM)-specific receptor but not leukemia inhibitory factor/OM receptor or interleukin-6 receptor. Complete block of OM-induced KS cell growth and OM binding by anti-gp130 antibodies. J Clin Invest. 1995 Sep;96(3):1319–1327. doi: 10.1172/JCI118167. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Murata T., Noguchi P. D., Puri R. K. Receptors for interleukin (IL)-4 do not associate with the common gamma chain, and IL-4 induces the phosphorylation of JAK2 tyrosine kinase in human colon carcinoma cells. J Biol Chem. 1995 Dec 22;270(51):30829–30836. doi: 10.1074/jbc.270.51.30829. [DOI] [PubMed] [Google Scholar]
  28. O'Donnell M. P., Kasiske B. L., Kim Y., Atluru D., Keane W. F. Lovastatin inhibits proliferation of rat mesangial cells. J Clin Invest. 1993 Jan;91(1):83–87. doi: 10.1172/JCI116204. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Obiri N. I., Debinski W., Leonard W. J., Puri R. K. Receptor for interleukin 13. Interaction with interleukin 4 by a mechanism that does not involve the common gamma chain shared by receptors for interleukins 2, 4, 7, 9, and 15. J Biol Chem. 1995 Apr 14;270(15):8797–8804. doi: 10.1074/jbc.270.15.8797. [DOI] [PubMed] [Google Scholar]
  30. Obiri N. I., Leland P., Murata T., Debinski W., Puri R. K. The IL-13 receptor structure differs on various cell types and may share more than one component with IL-4 receptor. J Immunol. 1997 Jan 15;158(2):756–764. [PubMed] [Google Scholar]
  31. Obiri N. I., Puri R. K. Characterization of interleukin-4 receptors expressed on human renal cell carcinoma cells. Oncol Res. 1994;6(9):419–427. [PubMed] [Google Scholar]
  32. Obiri N. I., Siegel J. P., Varricchio F., Puri R. K. Expression of high-affinity IL-4 receptors on human melanoma, ovarian and breast carcinoma cells. Clin Exp Immunol. 1994 Jan;95(1):148–155. doi: 10.1111/j.1365-2249.1994.tb06029.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Ohara J. Interleukin-4: molecular structure and biochemical characteristics, biological function, and receptor expression. Year Immunol. 1989;5:126–159. [PubMed] [Google Scholar]
  34. Park L. S., Friend D., Sassenfeld H. M., Urdal D. L. Characterization of the human B cell stimulatory factor 1 receptor. J Exp Med. 1987 Aug 1;166(2):476–488. doi: 10.1084/jem.166.2.476. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Paul W. E. Interleukin-4: a prototypic immunoregulatory lymphokine. Blood. 1991 May 1;77(9):1859–1870. [PubMed] [Google Scholar]
  36. Puri R. K., Debinski W., Obiri N., Kreitman R., Pastan I. Human renal cell carcinoma cells are sensitive to the cytotoxic effect of a chimeric protein composed of human interleukin-4 and Pseudomonas exotoxin. Cell Immunol. 1994 Apr 1;154(1):369–379. doi: 10.1006/cimm.1994.1084. [DOI] [PubMed] [Google Scholar]
  37. Puri R. K., Leland P., Kreitman R. J., Pastan I. Human neurological cancer cells express interleukin-4 (IL-4) receptors which are targets for the toxic effects of IL4-Pseudomonas exotoxin chimeric protein. Int J Cancer. 1994 Aug 15;58(4):574–581. doi: 10.1002/ijc.2910580421. [DOI] [PubMed] [Google Scholar]
  38. Puri R. K., Leland P., Obiri N. I., Husain S. R., Mule J., Pastan I., Kreitman R. J. An improved circularly permuted interleukin 4-toxin is highly cytotoxic to human renal cell carcinoma cells. Introduction of gamma c chain in RCC cells does not improve sensitivity. Cell Immunol. 1996 Jul 10;171(1):80–86. doi: 10.1006/cimm.1996.0176. [DOI] [PubMed] [Google Scholar]
  39. Puri R. K., Siegel J. P. Interleukin-4 and cancer therapy. Cancer Invest. 1993;11(4):473–486. doi: 10.3109/07357909309018879. [DOI] [PubMed] [Google Scholar]
  40. Reinecker H. C., Podolsky D. K. Human intestinal epithelial cells express functional cytokine receptors sharing the common gamma c chain of the interleukin 2 receptor. Proc Natl Acad Sci U S A. 1995 Aug 29;92(18):8353–8357. doi: 10.1073/pnas.92.18.8353. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Russell S. M., Keegan A. D., Harada N., Nakamura Y., Noguchi M., Leland P., Friedmann M. C., Miyajima A., Puri R. K., Paul W. E. Interleukin-2 receptor gamma chain: a functional component of the interleukin-4 receptor. Science. 1993 Dec 17;262(5141):1880–1883. doi: 10.1126/science.8266078. [DOI] [PubMed] [Google Scholar]
  42. Stürzl M., Roth W. K., Brockmeyer N. H., Zietz C., Speiser B., Hofschneider P. H. Expression of platelet-derived growth factor and its receptor in AIDS-related Kaposi sarcoma in vivo suggests paracrine and autocrine mechanisms of tumor maintenance. Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):7046–7050. doi: 10.1073/pnas.89.15.7046. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Taylor C. W., Grogan T. M., Salmon S. E. Effects of interleukin-4 on the in vitro growth of human lymphoid and plasma cell neoplasms. Blood. 1990 Mar 1;75(5):1114–1118. [PubMed] [Google Scholar]
  44. Toi M., Bicknell R., Harris A. L. Inhibition of colon and breast carcinoma cell growth by interleukin-4. Cancer Res. 1992 Jan 15;52(2):275–279. [PubMed] [Google Scholar]
  45. Vita N., Lefort S., Laurent P., Caput D., Ferrara P. Characterization and comparison of the interleukin 13 receptor with the interleukin 4 receptor on several cell types. J Biol Chem. 1995 Feb 24;270(8):3512–3517. doi: 10.1074/jbc.270.8.3512. [DOI] [PubMed] [Google Scholar]
  46. Werner S., Hofschneider P. H., Roth W. K. Cells derived from sporadic and AIDS-related Kaposi's sarcoma reveal identical cytochemical and molecular properties in vitro. Int J Cancer. 1989 Jun 15;43(6):1137–1144. doi: 10.1002/ijc.2910430629. [DOI] [PubMed] [Google Scholar]
  47. Yoshida D., Piepmeier J., Weinstein M. Estramustine sensitizes human glioblastoma cells to irradiation. Cancer Res. 1994 Mar 15;54(6):1415–1417. [PubMed] [Google Scholar]
  48. Zurawski S. M., Vega F., Jr, Huyghe B., Zurawski G. Receptors for interleukin-13 and interleukin-4 are complex and share a novel component that functions in signal transduction. EMBO J. 1993 Jul;12(7):2663–2670. doi: 10.1002/j.1460-2075.1993.tb05927.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Molecular Medicine are provided here courtesy of The Feinstein Institute for Medical Research at North Shore LIJ

RESOURCES